Prognostic Role of Lymphocyte-C-Reactive Protein Ratio in Colorectal Cancer: A Systematic Review and Meta Analysis

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Jul 25

PMID 35875086

Authors

Xinglong He

Ade Su

Yongcheng Xu

Diaolong Ma

Guoyuan Yang

Yiyun Peng

Jin Guo

Ming Hu

Yuntao Ma

Affiliations

Soon will be listed here.

Abstract

Introduction: The lymphocyte-C-reactive protein ratio (LCR) is a new immunoinflammatory score and prognostic marker, but the relationship between this index and the prognosis of colorectal cancer patients remains controversial.Therefore, aim of the study was to assess the relationship between LCR and prognosis for colorectal cancer patients through a systematic evaluation and meta-analysis.

Methods: We systematically searched PubMed, EMBASE, Web of Science, and Cochrane Library databases for randomized controlled studies and observational studies on the relationship between LCR and prognosis of colorectal cancer patients, all searched from the date of database creation to January 6, 2022.Our primary endpoints observed were overall survival (OS) and disease-free survival (DFS) of colorectal cancer patients, and secondary observables were basic characteristics of included studies, such as country, study duration, sample size, LCR threshold, and pathological characteristics of patients in each study, such as degree of differentiation, gender, tumor location, T stage, and lymphatic metastasis.

Results: A total of 10 case-control studies including 7068 patients were included. Meta-analysis results showed that overall survival (OS) and disease-free survival (DFS) were worse in colorectal cancer patients with lower levels of LCR (HR=0.44, 95% CI=0.38-0.52, P<0.001; HR=0.56, 95% CI=0.41-0.76, P< 0.001).Subgroup analysis based on country, study length, sample size, and LCR threshold showed that lower levels of LCR were all associated with poorer OS (P < 0.05). Regarding pathological characteristics, patients in the low LCR group were generally poorly differentiated (OR=1.79, 95% CI=1.55-2.07, P<0.001), while there was no significant relationship with gender, tumor location, T stage, and lymphatic metastasis (P>0.05).

Discussion/conclusion: LCR can be used as a prognostic marker for colorectal cancer patients, and patients with lower levels of LCR may have a poor prognosis. Due to the limitation of the number and quality of the included studies, the above findings need to be validated by more high-quality studies.

Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42022296563.

Citing Articles

Prognostic value of combined NP and LHb index with absolute monocyte count in colorectal cancer patients.

Wang K, Li K, Zhang Z, Zeng X, Sulayman S, Ababaike S Sci Rep. 2025; 15(1):8902.

PMID: 40087531 DOI: 10.1038/s41598-025-94126-7.

Types and Rates of COVID-19 Vaccination in Patients With Newly Diagnosed Microsatellite Stable and Instable Non-Metastatic Colon Cancer.

Akkus E, Karaoglan B, Akyol C, Unal A, Kuzu M, Savas B Cureus. 2024; 16(6):e61780.

PMID: 38975417 PMC: 11227084. DOI: 10.7759/cureus.61780.

Prognostic role of preoperative lymphocyte/C-reactive protein associated with upper gastrointestinal cancer: a meta-analysis.

Ye Y, Wu G, Yuan H, Zheng Y, Wang Y, Guo Q Front Oncol. 2023; 13:1181649.

PMID: 37849797 PMC: 10578962. DOI: 10.3389/fonc.2023.1181649.

Prognostic value of baseline C-reactive protein in diffuse large B-cell lymphoma: a systematic review and meta-analysis.

Huang Z, Wang K, Huang S, Lu Q Transl Cancer Res. 2023; 12(8):2169-2180.

PMID: 37701105 PMC: 10493799. DOI: 10.21037/tcr-23-1157.

C-reactive protein to lymphocyte ratio is a significant predictive factor for poor short-term clinical outcomes of SARS-CoV-2 BA.2.2 patients.

Xiao B, Wu Y, Liang H, Xiao J, Han Y, Yang Z Front Public Health. 2023; 11:1168375.

PMID: 37089472 PMC: 10117655. DOI: 10.3389/fpubh.2023.1168375.

References

Yasui K, Shida D, Nakamura Y, Ahiko Y, Tsukamoto S, Kanemitsu Y . Postoperative, but not preoperative, inflammation-based prognostic markers are prognostic factors in stage III colorectal cancer patients. Br J Cancer. 2020; 124(5):933-941. PMC: 7921100. DOI: 10.1038/s41416-020-01189-6. View

Artinyan A, Orcutt S, Anaya D, Richardson P, Chen G, Berger D . Infectious postoperative complications decrease long-term survival in patients undergoing curative surgery for colorectal cancer: a study of 12,075 patients. Ann Surg. 2014; 261(3):497-505. DOI: 10.1097/SLA.0000000000000854. View

Okugawa Y, Toiyama Y, Fujikawa H, Kawamura M, Yasuda H, Yokoe T . Cumulative perioperative lymphocyte/C-reactive protein ratio as a predictor of the long-term outcomes of patients with colorectal cancer. Surg Today. 2021; 51(12):1906-1917. DOI: 10.1007/s00595-021-02291-9. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Ullah W, Basyal B, Tariq S, Almas T, Saeed R, Roomi S . Lymphocyte-to-C-Reactive Protein Ratio: A Novel Predictor of Adverse Outcomes in COVID-19. J Clin Med Res. 2020; 12(7):415-422. PMC: 7331862. DOI: 10.14740/jocmr4227. View

Meng Y, Long C, Huang X, Huang L, Liao L, Tang W . Prognostic role and clinical significance of C-reactive protein-lymphocyte ratio in colorectal cancer. Bioengineered. 2021; 12(1):5138-5148. PMC: 8806856. DOI: 10.1080/21655979.2021.1960768. View

Toss M, Miligy I, Al-Kawaz A, Alsleem M, Khout H, Rida P . Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast. Mod Pathol. 2018; 31(8):1226-1236. DOI: 10.1038/s41379-018-0040-8. View

Ou W, Zhou C, Zhu X, Lin L, Xu Q . Prognostic Significance of Preoperative Lymphocyte-to-C-Reactive Protein Ratio in Patients with Non-Metastatic Colorectal Cancer. Onco Targets Ther. 2021; 14:337-346. PMC: 7811467. DOI: 10.2147/OTT.S290234. View

Kuang D, Zhao Q, Peng C, Xu J, Zhang J, Wu C . Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med. 2009; 206(6):1327-37. PMC: 2715058. DOI: 10.1084/jem.20082173. View

10.

Fridlender Z, Albelda S . Tumor-associated neutrophils: friend or foe?. Carcinogenesis. 2012; 33(5):949-55. DOI: 10.1093/carcin/bgs123. View

11.

Tredan O, Manuel M, Clapisson G, Bachelot T, Chabaud S, Bardin-Dit-Courageot C . Patients with metastatic breast cancer leading to CD4+ T cell lymphopaenia have poor outcome. Eur J Cancer. 2012; 49(7):1673-82. DOI: 10.1016/j.ejca.2012.11.028. View

12.

Barili F, Parolari A, Kappetein P, Freemantle N . Statistical Primer: heterogeneity, random- or fixed-effects model analyses?. Interact Cardiovasc Thorac Surg. 2018; 27(3):317-321. DOI: 10.1093/icvts/ivy163. View

13.

Murthy B, Thomson C, Dodwell D, Shenoy H, Mikeljevic J, Forman D . Postoperative wound complications and systemic recurrence in breast cancer. Br J Cancer. 2007; 97(9):1211-7. PMC: 2360477. DOI: 10.1038/sj.bjc.6604004. View

14.

Diakos C, Charles K, McMillan D, Clarke S . Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014; 15(11):e493-503. DOI: 10.1016/S1470-2045(14)70263-3. View

15.

Zhou C, Wu Y, Jiang L, Li Z, Diao P, Wang D . Density and location of CD3 and CD8 tumor-infiltrating lymphocytes correlate with prognosis of oral squamous cell carcinoma. J Oral Pathol Med. 2018; 47(4):359-367. DOI: 10.1111/jop.12698. View

16.

Herrmann D, Sinnett P, Holmes J, Khan S, Koller C, Vassar M . Statistical controversies in clinical research: publication bias evaluations are not routinely conducted in clinical oncology systematic reviews. Ann Oncol. 2017; 28(5):931-937. DOI: 10.1093/annonc/mdw691. View

17.

Nishi M, Shimada M, Tokunaga T, Higashijima J, Yoshikawa K, Kashihara H . Lymphocyte to C-reactive protein ratio predicts long-term outcomes for patients with lower rectal cancer. World J Surg Oncol. 2021; 19(1):201. PMC: 8262012. DOI: 10.1186/s12957-021-02319-x. View

18.

Okugawa Y, Toiyama Y, Yamamoto A, Shigemori T, Ide S, Kitajima T . Lymphocyte-C-reactive Protein Ratio as Promising New Marker for Predicting Surgical and Oncological Outcomes in Colorectal Cancer. Ann Surg. 2020; 272(2):342-351. DOI: 10.1097/SLA.0000000000003239. View

19.

Stang A . Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(9):603-5. DOI: 10.1007/s10654-010-9491-z. View

20.

Taniguchi Y, Kurokawa Y, Hagi T, Takahashi T, Miyazaki Y, Tanaka K . Methylprednisolone Inhibits Tumor Growth and Peritoneal Seeding Induced by Surgical Stress and Postoperative Complications. Ann Surg Oncol. 2019; 26(9):2831-2838. DOI: 10.1245/s10434-019-07585-4. View